Treg engineers take aim at autoimmunity

Elie Dolgin • November 9, 2021

Companies are deploying regulatory T cells, equipped with CAR and TCR constructs, to suppress immunity — locally and for the long term.

Engineered adoptive T-cell therapies have already transformed the treatment of blood cancers. Now, several startups hope to harness the power of regulatory T cells (Tregs) to suppress immune responses and offer tolerance to transplant recipients, or to control the inflammation driving autoimmune disorders.


Continue reading at Nature Biotechnology.

Yellow rings of DNA amidst white chromosomes
By Elie Dolgin September 11, 2025
Paul Mischel is championing the importance of odd rings of DNA in tumors — and their promise as targets for cancer therapy.
Artificially colored pancreatic islet cells
By Elie Dolgin September 5, 2025
Edits create cells that don’t trigger an immune response, allowing implant recipient to forego immune-suppressing drugs.